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Abstract 
Background: We described, in a large sample of patients with type 1 diabetes mellitus (T1DM) and GFR ≤ 60 mL/
min/1.73 m2 (with or without albuminuria), the differences in the clinical features associated with the two different 
chronic kidney disease phenotypes and we investigated, in a subset of patients, the modulating role of albuminuria 
on kidney disease progression.
Methods: Clinical data of 1395 patients with T1DM were extracted from electronic medical records.
Results: Albuminuria was detected in 676 (48.5%) patients, with the remaining 719 (51.5%) patients having nor-
moalbuminuric renal impairment. Those with albuminuria showed an evident worse cardiovascular risk profile as 
compared to patients with normoalbuminuria. A subgroup of 582 patients was followed up over a 4-year period. One 
hundred and twenty five patients (21.5%) showed a loss of eGFR > 30%. The proportion of patients reaching the renal 
outcome was significantly higher among those with baseline albuminuria as compared to patients with normoal-
buminuria (P < 0.0001). At the multivariate logistic analysis microalbuminuria, macroalbuminuria and proliferative 
retinopathy were the only parameters independently associated to eGFR reduction.
Conclusions: The proportion of T1DM patients with normoalbuminuria renal impairment is high (about 50%). These 
patients have a slower eGFR decline as compared to that observed in patients with albuminuria renal impairment.
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Background
Diabetic kidney disease (DKD), an important complica-
tion of diabetes mellitus, is the leading cause of kidney 
failure in the western word and it is also associated with 
increased cardiovascular morbidity and mortality. Albu-
minuria and reduced glomerular filtration rate (GFR) 
are the key features of DKD. Traditionally, the earliest 
clinical manifestation of DKD has been the detection of 
persistent microalbuminuria [1]. Early studies suggested 
that GFR starts to decrease only when albuminuria 
reaches the macroalbuminuric range [2]. This conven-
tional paradigm of kidney disease in people with diabe-
tes has been recently challenged. Changes in albuminuria 
and GFR are being increasingly recognized as comple-
mentary rather than obligatory manifestations of DKD. 
Furthermore, albuminuria and loss of GFR seem to be 
associated with distinct clusters of specific risk factors. 
Several studies investigating the prevalence of both nor-
moalbuminuric and albuminuric chronic kidney disease 
(CKD) have been performed in type 2 diabetes mellitus 
(T2DM) [3–7]. Limited information is available concern-
ing heterogeneity of renal features in patients with type 
1 diabetes mellitus (T1DM) and this is largely result-
ing from studies conducted in a few cohorts of patients 
with GFR ≤ 60 mL/min/1.73 m2 [8–10]. Recently, Penno 
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correlates of different CKD phenotypes in a cohort of 777 
patients with T1DM (of which 29 with eGFR < 60  mL/
min/1.73  m2). They found that normoalbuminuric CKD 
phenotype is present in a significant proportion of the 
T1DM, a finding supporting two distinct pathways, with 
and without albuminuria, to advanced kidney disease.
We therefore analyzed a large sample of patients with 
T1DM and GFR ≤ 60  mL/min/1.73  m2 (with or without 
albuminuria) attending diabetes clinics and representa-
tive of current clinical practice for diabetes care in Italy 
to describe the differences in the clinical features asso-
ciated with the two different CKD phenotypes (i.e. with 
and without albuminuria) and to investigate, in a subset 
of patients, the modulating role of albuminuria on kidney 
disease progression.
Methods
In this report, we show the results of an analysis per-
formed using the data set of the electronic medical 
records collected on a large sample of patients with a 
diagnosis of T1DM (according to American Diabetes 
Association 2003 criteria), who attended 295 diabetes 
clinics in Italy between 1 January 2004, and 31 Decem-
ber 2011. Approximately, one-third of all the Italian 
diabetes clinics were involved in this study, evenly dis-
tributed throughout the country and therefore indicative 
of the clinical practice. For the purpose of the analysis, 
we considered only patients who were aged 18  years or 
older, with at least 1 outpatient measurement of serum 
creatinine and albuminuria and with a GFR ≤ 60  mL/
min/1.73 m2. A total of 1395 patients (654 males and 741 
females) constituted the study population (Additional 
file 1: Fig. S1).
The database derives from the Italian Association of 
Clinical Diabetologists (Associazione Medici Diabe-
tologi—AMD) initiative designed to monitor diabetes 
care and quality of care as previously reported [11–13]. 
All participating clinics used an electronic clinical record 
system, and a software specifically developed to extract 
information. Data from all participating clinics were col-
lected anonymously and were centrally analyzed [11–13]. 
The results were internally approved by the AMD Annals 
scientific committee. The core data-set included meas-
ures and monitoring of glycated hemoglobin (HbA1c), 
total cholesterol, low-density lipoprotein cholesterol 
(LDL-c) or high density lipoprotein cholesterol (HDL-c), 
and triglycerides. The use of specific classes of drugs was 
also evaluated. Kidney function was assessed by serum 
creatinine, measured by modified Jaffè method, and uri-
nary albumin excretion measurements (UAE). Glomeru-
lar filtration rate (GFR) was estimated for each patient 
by using the CKD epidemiology collaboration formula 
derived by serum creatinine values [14]. Increased UAE 
was diagnosed as (1) microalbuminuria if urinary albu-
min concentration was > 30 and ≤ 300  mg/L, or if UAE 
rate was > 20 and ≤ 200 μg/min, or if urinary albumin-to-
creatinine ratio was > 2.5 mg/mmol in men and > 3.5 mg/
mmol in women and ≤ 30 mg/mmol in both gender and 
(2) macroalbuminuria if urinary albumin concentration 
was > 300  mg/L, or if UAE rate was > 200  μg/min, or if 
albumin-to-creatinine ratio was > 30  mg/mmol in both 
gender. Urine albumin excretion was evaluated by means 
of urine albumin concentration in the majority of study 
patients 1020 (i.e. 73%) and by albumin to creatinine ratio 
(spot morning samples) in a smaller number of patients 
344 (25%). Timed urine collection (24  h) was used in a 
minority of patients 31 (2%).
Albuminuria indicates patients with either microal-
buminuria or macroalbuminuria. DKD was defined as 
diabetes with albuminuria and/or low GFR (≤ 60  mL/
min/1.73  m2). Information on the presence of diabetic 
retinopathy, background (BR), or proliferative (PR), was 
also available. At each participating center, all patients 
underwent physical examination and blood pressure (BP) 
measurements according to a standardized protocol. BP 
was measured with the patient in the sitting position 
after a 5-min rest, with a mercury sphygmomanometer.
For the cross-sectional analyses, we extracted data 
from the most recent patients’ visit complete of eGFR 
measurement and albuminuria evaluation. To obtain the 
4-year evaluations, we selected for each patient the last 
4-year period that included eGFR and albuminuria status 
at baseline and a re-evaluation of eGFR 4 years later. As 
a consequence of selection criteria, the baseline included 
a visit up to the year 2008 and the follow-up up to 2011 
(range of visits 48 ± 6  months selecting that closest to 
48 month). For patients without a re-evaluation at 4-year, 
the last visit up to the year 2008 was considered for the 
cross-sectional study (the same period of baseline visit 
for the longitudinal population).
Statistical analysis
Data are given as mean value ± standard deviation or 
median (interquartile range), and categorical variables 
are described as frequencies and percentages. Logis-
tic regression analysis was used to evaluate variables 
associated to albuminuria. Predictors of eGFR reduc-
tion > 30% [15] than baseline were evaluated with a 
logistic model adjusting for baseline eGFR. A multi-
variate model was built selecting variables associated 
to the outcome with a P value < 0.05 adjusting for age 
and gender. Multivariate analysis was performed as 
complete-case analysis including patients with all data 
available. The odds ratios (ORs) were used to estimate 
the degree of association with outcome. Assuming 
linearity of eGFR reduction over time, its slope was 
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taken as a measure of disease progression rate. For 
each patients, we calculated the regression coefficient 
(slope) of linear regression between eGFR value and 
the exact time in years from the first evaluation includ-
ing all measurements from baseline to the 4-year visit. 
The analyses were made using STATA software, Version 
14 (StataCorp, College Station, TX). P values of < 0.05 
were considered statistically significant.
Results
The main clinical features of the study population 
(n = 1395) at baseline, as a whole and grouped by 
the presence/absence of albuminuria, are summa-
rized in Table  1. Overall, the mean age of patients was 
63 ± 14  years, 46.9% were male and mean duration of 
diabetes was 27 ± 14  years. Taking into account the 
presence of CKD, glycemic and blood pressure controls 
were fairly good. A total of 986 (70.7%) and 611 (43.8%) 
Table 1 Baseline clinical characteristics of  1395 T1DM patients with  low eGFR as  whole and  after  stratification 
by the presence of albuminuria
Mean ± SD or absolute frequency (percentage). Patients’ baseline missing data: duration of diabetes 72 (5.2%), BMI 212 (15.2%), serum uric acid 542 (38.9%), HbA1c 11 
(0.8%), total cholesterol 73 (5.2%), triglycerides 92 (6.6%), HDL 99 (7.1%), LDL 110 (7.9%), blood pressure 255 (18.3%), smokers 823 (59.0%). Serum uric acid in the top 
gender-specific quintile: > 6.6 mg/dL in females and > 7.4 mg/dL in males
eGFR estimated glomerular filtration rate, BMI body mass index, HbA1c glycated haemoglobin, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein 
cholesterol, ACE-Is angiotensin converting enzyme-inhibitors, ARBs angiotensin II receptor antagonists
Overall Normoalbuminuria Albuminuria P
n = 1395 n = 719 n = 676
Male sex 654 (46.9%) 252 (35.0%) 402 (59.5%) < 0.001
Age (years) 63 ± 14 66 ± 12 60 ± 14 < 0.001
Duration of diabetes (years) 27 ± 14 27 ± 15 27 ± 13 0.968
BMI (kg/m2) 26.3 ± 4.7 26.2 ± 4.5 26.5 ± 4.9 0.201
Serum creatinine (mg/dL) 1.55 ± 0.81 1.35 ± 0.52 1.78 ± 0.98 < 0.001
eGFR (mL/min/1.73 m2) 46 ± 12 49 ± 10 43 ± 13 < 0.001
Albuminuria 676 (48.5%) – –
Serum uric acid (mg/dL) 5.7 ± 1.8 5.3 ± 1.8 6.1 ± 1.6 < 0.001
Serum uric acid in the top quintile 162 (19.0%) 60 (14.3%) 102 (23.5%) 0.001
HbA1c (%) 8.2 ± 1.6 8.0 ± 1.5 8.3 ± 1.7 < 0.001
HbA1c (mmol/mol) 66 ± 17.5 64.0 ± 16.4 67 ± 18.6 < 0.001
HbA1c ≥ 7% 1071 (77.4%) 541 (75.7%) 530 (79.2%) 0.114
HbA1c ≥ 54 mmol/mol 1071 (77.4%) 541 (75.7%) 530 (79.2%) 0.114
Total cholesterol (mg/dL) 195 ± 44 192 ± 38 198 ± 48 0.012
Triglycerides (mg/dL) 122 ± 82 110 ± 74 136 ± 89 < 0.001
Triglycerides  ≥ 150 mg/dL 292 (22.4%) 113 (16.8%) 179 (28.5%) < 0.001
HDL (mg/dL) 60 ± 19 61 ± 19 58 ± 20 0.008
HDL < 40 M < 50 F mg/dL 269 (20.8%) 133 (20.0%) 136 (21.6%) 0.491
LDL (mg/dL) 112 ± 35 109 ± 32 114 ± 38 0.027
LDL ≥ 100 mg/dL 785 (61.1%) 402 (60.4%) 383 (61.9%) 0.578
Systolic BP (mmHg) 139 ± 20 137 ± 20 141 ± 20 < 0.001
Diastolic BP (mmHg) 77 ± 10 76 ± 10 78 ± 10 0.006
Blood pressure ≥ 140/85 mmHg 659 (57.8%) 315 (53.9%) 344 (61.9%) 0.007
Non-proliferative retinopathy 279 (20.0%) 152 (21.1%) 127 (18.8%) 0.272
Proliferative retinopathy 146 (10.5%) 56 (7.8%) 90 (13.3%) 0.001
Smokers 107 (18.7%) 40 (13.5%) 67 (24.3%) 0.001
Lipid-lowering treatment 611 (43.8%) 301 (41.9%) 310 (45.9%) 0.133
Treatment with statins 579 (41.5%) 287 (39.9%) 292 (43.2%) 0.214
Treatment with fibrates 14 (1.0%) 9 (1.3%) 5 (0.7%) 0.343
Antihypertensive treatment 986 (70.7%) 453 (63.0%) 533 (78.8%) < 0.001
Treatment with ACE-Is/ARBs 862 (61.8%) 384 (53.4%) 478 (70.7%) < 0.001
Aspirin 339 (24.3%) 158 (22.0%) 181 (26.8%) 0.037
Insulin pump 52 (3.7%) 17 (2.4%) 35 (5.2%) 0.007
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patients were on antihypertensive and on lipid-lowering 
treatment, respectively. In our sample, albuminuria was 
detected in 676 (48.5%) patients, with the remaining 719 
(51.5%) patients having normoalbuminuric renal impair-
ment (Table 1). Those with albuminuria were more likely 
to be males and, on average, younger respect to patients 
without albuminuria. Duration of disease was compa-
rable between patients with or without albuminuria. 
Albuminuria was also associated with a worse glycemic 
control and higher levels of serum uric acid. Furthermore, 
albuminuria was associated with a more atherogenic lipid 
profile (i.e. higher LDL cholesterol and triglycerides lev-
els and lower HDL-c) and higher values of systolic BP 
(SBP) and diastolic BP (DBP) despite a greater prevalence 
of antidyslipidemic and antihypertensive treatment.
As expected, individuals with albuminuria were more 
frequently treated with angiotensin converting enzyme 
inhibitors (ACE-Is) or angiotensin II receptor antago-
nists (ARBs) as compared to those without albuminuria. 
Moreover, they were more likely to be smokers and to 
show proliferative retinopathy.
We have also compared clinical features of patients 
with micro or macroalbuminuria. Those with macroal-
buminuria showed an evident worse cardiovascular (CV) 
risk profile as compared to patients with microalbuminu-
ria (Additional file 2: Table S1).
To investigate the differences in the kidney dysfunc-
tion progression between patients with low eGFR and 
normoalbuminuria or albuminuria, a subgroup of 582 
patients, whose clinical features are showed in Table  2 
and Additional file  2: Table  S2, was followed up over a 
4-year period. One hundred and twenty five patients 
(21.5%) showed a loss of eGFR > 30%. The proportion 
of patients reaching the renal outcome was significantly 
higher among those with baseline albuminuria as com-
pared to patients with normoalbuminuria (33.6% vs 
10.5%, albuminuria vs normoalbuminuria, respectively 
P < 0.0001). The slope of GFR decline was of − 0.5 (− 2.2; 
1.5) mL/min/1.73 m2/year for the whole sample. Patients 
with normoalbuminuria showed a stable kidney func-
tion along the follow-up period [i.e. + 0.4 (− 1.2; 3.2) mL/
min/1.73  m2/year] while those with albuminuria had a 
significant progression of kidney disease [− 1.3 (− 3.2; 
0.3)  mL/min/1.73  m2/year]. The main baseline clinical 
features of the above study population grouped by renal 
outcome at 4-year follow-up are summarized in Table 3. 
Patients who went on to develop renal outcome showed 
a poor glycemic control and higher levels of triglycerides 
and serum uric acid as compared to patients who did 
not. Furthermore, they had higher levels of SBP despite a 
greater prevalence of antihypertensive treatment.
As expected, they had also a lower eGFR at baseline (43 
vs. 48 mL/ min/1.73 m2, P < 0.001).
Almost 2/3 of patients who went on to develop eGFR 
reduction > 30% showed albuminuria at baseline and 
19% showed proliferative retinopathy. At the multivariate 
logistic analysis microalbuminuria, macroalbuminuria 
and proliferative retinopathy were the only parameters 
independently associated to eGFR reduction (Table 4).
Discussion
In a large cohort representative of real life clinical prac-
tice in Italy, we found that up to 50% of patients with 
T1DM and CKD show a non albuminuric phenotype. In 
addition, we demonstrate that the loss of GFR is much 
greater in T1DM albuminuric CKD as compared with 
T1DM normoalbuminuric CKD patients.
The prevalence of normoalbuminuric CKD in our 
population was higher than that in the Finnish Dia-
betic Nephropathy Study [16] where, of the 502 patients 
with CKD, 78 (16%) did not have albuminuria. This dif-
ference could likely be accounted for by differences in 
patients’ clinical features and in setting were the patients 
have been studied. A cross-sectional survey of the UK 
National Diabetes Audit [9] investigating a large cohort 
of T1DM patients has recently reported the presence 
of normoalbuminuria in 54.4% of individuals stage ≥ 3 
CKD, a proportion similar to our finding. In a very recent 
retrospective study by Penno et al. [10], the authors found 
that, among 29 patients with eGFR < 60 mL/min/1.73 m2, 
17 (58.6%) had normoalbuminuria. The authors couldn’t 
find any significant differences for most of clinical varia-
bles investigated, very likely because of the small number 
of patients evaluated. Furthermore, the study conducted 
by Penno et al. was a cross-sectional, single-centre study 
while in our study the patients were recruited from more 
than 200 diabetes clinics in Italy distributed throughout 
the country and therefore indicative of the clinical prac-
tice in the real life condition. The pathophysiology and 
clinical significance of low GFR levels in patients without 
albuminuria is to this day unclear. While in patients with 
T2DM the occurrence of non albuminuric renal impair-
ment has been related to pathogenetic mechanisms such 
as premature kidney senescence, interstitial fibrosis, 
ischaemic vascular disease or cholesterol microemboli 
[3] which may differ from those involved in the develop-
ment of traditional diabetic glomerulosclerosis, it is cur-
rently uncertain whether a similar pathogenetic scenario 
also applies to T1DM patients with non albuminuric 
renal dysfunction.  Glomerular structural changes typi-
cal of diabetic nephropathy, have been reported in T1DM 
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Table 2 Baseline clinical characteristics of 582 type 1 diabetes mellitus patients with low eGFR and with 4 year follow-up, 
overall and on the basis of albuminuria
Mean ± SD, median (interquartile range) or absolute frequency (percentage). Patients’ baseline missing data: duration of diabetes 18 (3.1%), BMI 108 (18.6%), serum 
uric acid 225 (38.7%), HbA1c 5 (0.9%), total cholesterol 41 (7.0%), triglycerides 48 (8.2%), HDL 50 (8.6%), LDL 53 (9.1%), blood pressure 116 (19.9%), smokers 337 
(57.9%)
eGFR estimated glomerular filtration rate, BMI body mass index, HbA1c glycated haemoglobin, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein 
cholesterol, ACE-Is angiotensin converting enzyme-inhibitors, ARBs angiotensin II receptor antagonists
Overall Normoalbuminuria Albuminuria P
n = 582 n = 305 n = 277
Male sex 262 (45.0%) 99 (32.5%) 163 (58.8%) < 0.001
Age (years) 63 ± 13 65 ± 12 60 ± 13 < 0.001
Duration of diabetes (years) 27 ± 13 26 ± 14 27 ± 12 0.385
BMI (kg/m2) 27 ± 5 26 ± 4 27 ± 6 0.085
Serum creatinine (mg/dL) 1.55 ± 0.90 1.31 ± 0.40 1.81 ± 1.19 < 0.001
eGFR (mL/min/1.73 m2) 47 ± 12 50 ± 10 43 ± 13 < 0.001
eGFR (mL/min/1.73 m2) 50 (39–56) 52 (45–57) 46 (35–54) < 0.001
Serum uric acid (mg/dL) 5.6 ± 1.6 5.1 ± 1.4 6.1 ± 1.6 < 0.001
Serum uric acid in the top quintile 65 (18.2%) 20 (11.4%) 45 (24.7%) 0.001
HbA1c (%) 8.1 ± 1.5 8.0 ± 1.3 8.3 ± 1.6 0.036
HbA1c (mmol/mol) 65 ± 16.4 64 ± 14.2 67 ± 17.5 0.036
HbA1c ≥ 7% 453 (78.5%) 234 (77.2%) 219 (79.9%) 0.431
HbA1c ≥ 54 mmol/mol 453 (78.5%) 234 (77.2%) 219 (79.9%) 0.431
Total cholesterol (mg/dL) 196 ± 40 197 ± 37 195 ± 43 0.677
Triglycerides (mg/dL) 121 ± 81 110 ± 82 133 ± 79 0.002
Triglycerides ≥ 150 mg/dL 118 (22.1%) 46 (16.6%) 72 (28.0%) 0.002
HDL (mg/dL) 59 ± 19 62 ± 19 57 ± 18 0.004
HDL < 40 M < 50 F mg/dL 105 (19.7%) 54 (19.5%) 51 (20.0%) 0.884
LDL (mg/dL) 113 ± 33 113 ± 31 112 ± 35 0.636
LDL ≥ 100 mg/dL 349 (66.0%) 188 (68.1%) 161 (63.6%) 0.278
Systolic BP (mmHg) 139 ± 19 137 ± 19 141 ± 19 0.032
Diastolic BP (mmHg) 77 ± 9 77 ± 9 78 ± 10 0.204
Blood pressure  ≥ 140/85 mmHg 276 (59.2%) 138 (56.1%) 138 (62.7%) 0.146
Non-proliferative retinopathy 123 (21.1%) 64 (21.0%) 59 (21.3%) 0.926
Proliferative retinopathy 68 (11.7%) 24 (7.9%) 44 (15.9%) 0.003
Smokers 46 (18.8%) 20 (14.5%) 26 (24.3%) 0.053
Lipid-lowering treatment 253 (43.5%) 124 (40.7%) 129 (46.6%) 0.151
Treatment with statins 238 (40.9%) 115 (37.7%) 123 (44.4%) 0.101
Treatment with fibrates 8 (1.4%) 5 (1.6%) 3 (1.1%) 0.568
Antihypertensive treatment 421 (72.3%) 199 (65.2%) 222 (80.1%) < 0.001
Treatment with ACE-Is/ARBs 372 (63.9%) 171 (56.1%) 201 (72.6%) < 0.001
Aspirin 139 (23.9%) 67 (22.0%) 72 (26.0%) 0.256
Insulin pump 18 (3.1%) 2 (0.7%) 16 (5.8%) 0.003
4-year eGFR reduction > 30% 125 (21.5%) 32 (10.5%) 93 (33.6%) < 0.001
eGFR at follow-up (mL/min/1.73 m2) 47 (33–58) 53 (41–66) 38 (25–49) < 0.001
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patients with normoalbuminuria and reduced GFR [17]. 
In these patients, a thickening of the glomerular basal 
membrane and a greater fractional volume of the glomer-
ulus occupied by mesangium have been found as com-
pared with those who had a normal GFR. Probably the 
expression of some proteins, such as nephrin, responsible 
of the integrity of the slit diaphragm, remains unchanged 
in patients with normoalbuminuric renal insufficiency 
[18].
When we focused on differences in the kidney dys-
function progression we found that the loss of GFR was 
greater in albuminuric CKD patients as compared to 
normoalbuminuric CKD patients. Patients with nor-
moalbuminuria showed a stable kidney function along 
the follow-up period while those with albuminuria had 
a significant progression of kidney disease. This finding 
is in line with the results of Holfiel et al. who described 
the accelerating effect of albuminuria in the loss of GFR 
in patients with T1DM and T2DM [19]. Normoalbu-
minuric renal impairment is a widely described strong 
risk factor for cardiovascular mortality and morbidity 
in the general population and in patients with T2DM 
[20]. Data on this specific issue in patients with T1DM 
are lacking.
Our study has several limitations as well as strengths. 
First of all, laboratory variables were not centralized and 
this could have caused variability especially in the cre-
atinine assay. However, most laboratories around the 
country currently use the modified Jaffè method, which 
has good reproducibility. In addition, we have classified 
our patients using only one measurement of albuminuria. 
This is in line with other studies [21, 22]. Pugliese et al. 
[21] have recently reported in a large cohort of subjects 
with T2DM participating in the renal insufficiency and 
cardiovascular events (RIACE) Italian Multicentre Study, 
that a single UAE value, thought to be encumbered with 
high intra-individual variability, is an accurate predic-
tor of nephropathy stage for clinical and epidemiologi-
cal purposes. On the other hand, the large number of 
patients studied and the consistent geographical distribu-
tion of the recruiting centers are major strengths of the 
study, which gives missing information about this issue in 
Italy. Further limitations merit to be mentioned, i.e. lack 
of information on: (i) previous cardiovascular events, 
cancer, infection and hospitalization during the follow-
up period, (ii) historical albuminuria data and (iii) dura-
tion of smoking habit.
In conclusion, our study shows as the propor-
tion of T1DM patients with normoalbuminuria renal 
impairment is high (about 50%). These patients have a 
slower eGFR decline as compared to that observed in 
patients with albuminuria renal impairment. Whether 
T1DM patients with albuminuric renal impairment 
Table 3 Baseline clinical characteristics of  582 type 1 
diabetes mellitus patients reaching the  renal end-point 
(estimated Glomerular filtration rate reduction > 30%)
Mean ± SD or absolute frequency (percentage). Patients’ baseline missing data: 
duration of diabetes 18 (3.1%), BMI 108 (18.6%), serum uric acid 225 (38.7%), 
HbA1c 5 (0.9%), total cholesterol 41 (7.0%), triglycerides 48 (8.2%), HDL 50 
(8.6%), LDL 53 (9.1%), blood pressure 116 (19.9%), smokers 337 (57.9%)
eGFR estimated glomerular filtration rate, BMI body mass index, HbA1c glycated 
haemoglobin, HDL high-density lipoprotein cholesterol, LDL low-density 
lipoprotein cholesterol, ACE-Is angiotensin converting enzyme-inhibitors, ARBs 
angiotensin II receptor antagonists
The P value refers to the effect of each variable on 4-year eGFR reduction > 30% 





n = 457 n = 125
Male sex 197 (43.1%) 65 (52.0%) 0.149
Age (years) 63 ± 13 61 ± 14 0.295
Known duration of diabetes (years) 27 ± 13 27 ± 13 0.726
BMI (kg/m2) 26 ± 5 27 ± 6 0.277
Serum creatinine (mg/dL) 1.49 ± 0.86 1.75 ± 1.02 0.501
eGFR (mL/min/1.73 m2) 48 ± 11 43 ± 13 < 0.001
Albuminuria 184 (40.3%) 93 (74.4%) < 0.001
Microalbuminuria 131 (28.7%) 41 (32.8%) 0.001
Macroalbuminuria 53 (11.6%) 52 (41.6%) < 0.001
Serum uric acid (mg/dL) 5.4 ± 1.5 6.2 ± 1.8 0.004
Serum uric acid in the top gender-
specific quintile
40 (14.5%) 25 (30.9%) 0.038
HbA1c (%) 8.1 ± 1.4 8.4 ± 1.5 0.049
HbA1c (mmol/mol) 65 ± 15.3 68 ± 16.4 0.049
HbA1c ≥ 7% 350 (77.3%) 103 (83.1%) 0.129
HbA1c ≥ 53 mmol/mol 350 (77.3%) 103 (83.1%) 0.129
Total cholesterol (mg/dL) 196 ± 38 196 ± 48 0.912
Triglycerides (mg/dL) 114 ± 63 147 ± 125 0.003
Triglycerides ≥ 150 mg/dL 84 (19.9%) 34 (30.4%) 0.054
HDL (mg/dL) 60 ± 19 56 ± 18 0.086
HDL < 40 M < 50 F mg/dL 81 (19.2%) 24 (21.8%) 0.791
LDL (mg/dL) 113 ± 30 112 ± 42 0.964
LDL ≥ 100 mg/dL 280 (66.8%) 69 (62.7%) 0.585
Systolic BP (mmHg) 138 ± 19 143 ± 20 0.040
Diastolic BP (mmHg) 77 ± 9 78 ± 10 0.128
BP ≥ 140/85 mmHg 208 (57.3%) 68 (66.0%) 0.092
Non-proliferative retinopathy 99 (21.7%) 24 (19.2%) 0.850
Proliferative retinopathy 44 (9.6%) 24 (19.2%) 0.008
Smokers 32 (16.8%) 14 (25.9%) 0.060
Lipid-lowering treatment 193 (42.2%) 60 (48.0%) 0.302
Treatment with statins 184 (40.3%) 54 (43.2%) 0.589
Treatment with fibrates 5 (1.1%) 3 (2.4%) 0.308
Antihypertensive treatment 317 (69.4%) 104 (83.2%) 0.010
Treatment with ACE-Is/ARBs 284 (62.1%) 88 (70.4%) 0.226
Aspirin 107 (23.4%) 32 (25.6%) 0.715
Insulin pump 10 (2.2%) 8 (6.4%) 0.050
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as compared to patients with normoalbuminuric 
renal impairment need a more intensive renal protec-
tion treatment will be clarified by further intervention 
studies.
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